Tags

Type your tag names separated by a space and hit enter

The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in Egyptian patients.
Immunol Invest. 2010; 39(8):820-32.II

Abstract

Osteopenia and osteoporosis are considered major health problems in patients suffering from thalassemia due to increased life expectancy of those patients. Osteoprotegerin (OPG) and receptor activator of NF-kappa-B ligand (RANKL) have been recently implicated in the pathogenesis of various types of osteoporosis. The aim of this study is to evaluate the role of serum OPG/RANKL ratio in patients suffering from thalassemia complicated with osteoporosis. Serum OPG and RANKL were measured in thalassemia patients and 20 healthy control subjects, using ELISA methods. Stastistically, the results demonstrate lower OPG and OPG/RANKL ratio in patients suffering from thalassemia with documented osteopenia or osteoporosis in comparison with control group and patients suffering from thalassemia without osteopenia or osteoporosis. OPG/RANKL ratio could become a promising rapid and cheap screening marker for osteopenia or osteoporosis in patients suffering from thalassemia. Furthermore, OPG may become a therapeutic option in treatment of osteoporosis of various etiologies including thalassemia.

Authors+Show Affiliations

Department of Clinical Pathology, Zagazig Faculty of Medicine, Zagazig, Egypt.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20718662

Citation

Salah, Hosam, et al. "The Clinical Significance of OPG/sRANKL Ratio in Thalassemia Patients Suffering From Osteopenia or Osteoporosis in Egyptian Patients." Immunological Investigations, vol. 39, no. 8, 2010, pp. 820-32.
Salah H, Atfy M, Fathy A, et al. The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in Egyptian patients. Immunol Invest. 2010;39(8):820-32.
Salah, H., Atfy, M., Fathy, A., Atfy, M., Mansor, H., & Saeed, J. (2010). The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in Egyptian patients. Immunological Investigations, 39(8), 820-32. https://doi.org/10.3109/08820139.2010.498492
Salah H, et al. The Clinical Significance of OPG/sRANKL Ratio in Thalassemia Patients Suffering From Osteopenia or Osteoporosis in Egyptian Patients. Immunol Invest. 2010;39(8):820-32. PubMed PMID: 20718662.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in Egyptian patients. AU - Salah,Hosam, AU - Atfy,Maha, AU - Fathy,Ayman, AU - Atfy,Mervat, AU - Mansor,Hosam, AU - Saeed,Jehan, Y1 - 2010/08/18/ PY - 2010/8/20/entrez PY - 2010/8/20/pubmed PY - 2011/2/22/medline SP - 820 EP - 32 JF - Immunological investigations JO - Immunol. Invest. VL - 39 IS - 8 N2 - Osteopenia and osteoporosis are considered major health problems in patients suffering from thalassemia due to increased life expectancy of those patients. Osteoprotegerin (OPG) and receptor activator of NF-kappa-B ligand (RANKL) have been recently implicated in the pathogenesis of various types of osteoporosis. The aim of this study is to evaluate the role of serum OPG/RANKL ratio in patients suffering from thalassemia complicated with osteoporosis. Serum OPG and RANKL were measured in thalassemia patients and 20 healthy control subjects, using ELISA methods. Stastistically, the results demonstrate lower OPG and OPG/RANKL ratio in patients suffering from thalassemia with documented osteopenia or osteoporosis in comparison with control group and patients suffering from thalassemia without osteopenia or osteoporosis. OPG/RANKL ratio could become a promising rapid and cheap screening marker for osteopenia or osteoporosis in patients suffering from thalassemia. Furthermore, OPG may become a therapeutic option in treatment of osteoporosis of various etiologies including thalassemia. SN - 1532-4311 UR - https://www.unboundmedicine.com/medline/citation/20718662/The_clinical_significance_of_OPG/sRANKL_ratio_in_thalassemia_patients_suffering_from_osteopenia_or_osteoporosis_in_Egyptian_patients_ L2 - http://www.tandfonline.com/doi/full/10.3109/08820139.2010.498492 DB - PRIME DP - Unbound Medicine ER -